Sartorius AG
Company Profile
Business description
Sartorius AG is a leading provider of bioprocessing solutions. Its bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs, and has a focus on single-use technology. Its laboratory products and services division offers a wide range of products for laboratory use, including scales, pipettes, and filtration equipment. As of 2024, the bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 72% ownership and 83% voting control. The business is geographically diverse, with revenue across Europe, Middle East, and Africa (41% of 2024 sales), the Americas (36%), and Asia-Pacific (23%). We estimate China revenue to be around 10%.
Contact
Otto-Brenner-Strasse 20
GottingenNI37079
DEUT: +49 5513080
Sector
Healthcare
Stock type
Defensive
Industry
Medical Instruments & Supplies
Fiscal Year End
31 December 2025
Employees
13,878
Stocks News & Analysis
stocks
Investors overly negative on cheap ASX share
stocks
Overvalued US AI play reports earnings
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,875.70 | 32.60 | 0.37% |
| CAC 40 | 8,150.64 | 64.59 | 0.80% |
| DAX 40 | 24,199.50 | 238.91 | 1.00% |
| Dow JONES (US) | 47,890.87 | 4.90 | 0.01% |
| FTSE 100 | 9,837.77 | 63.45 | 0.65% |
| HKSE | 25,498.13 | 29.35 | 0.12% |
| NASDAQ | 22,951.64 | 258.32 | 1.14% |
| Nikkei 225 | 49,001.50 | 510.78 | -1.03% |
| NZX 50 Index | 13,256.77 | 39.14 | -0.29% |
| S&P 500 | 6,763.04 | 41.61 | 0.62% |
| S&P/ASX 200 | 8,588.20 | 31.70 | 0.37% |
| SSE Composite Index | 3,876.37 | 6.09 | 0.16% |